Bill

Bill > HR1492


US HR1492

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.


summary

Introduced
02/21/2025
In Committee
02/21/2025
Crossed Over
Passed
Dead

Introduced Session

119th Congress

Bill Summary

A BILL To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

AI Summary

This bill proposes to amend the existing Drug Price Negotiation Program by changing the negotiation period for biologic drugs from 7 years to 11 years, effectively equalizing the negotiation timeline between small-molecule drugs and biologic drugs. In the context of pharmaceutical regulation, small-molecule drugs are traditional chemically synthesized medicines, while biologic drugs are complex medications derived from living organisms. The bill modifies a specific section of the Social Security Act (Section 1192(e)(1)(A)(ii)) to extend the period during which these biologic drugs are protected from price negotiations. The amendment would be applied retroactively, as if it had been included in the original enactment of Public Law 117-169 (which is likely referring to the Inflation Reduction Act of 2022 that originally established the Drug Price Negotiation Program). By extending the negotiation period for biologics, the bill aims to provide additional time for pharmaceutical companies to recoup research and development costs for these complex and often more expensive medications.

Committee Categories

Business and Industry

Sponsors (58)

Greg Murphy (R)* Rick Allen (R),  Mark Amodei (R),  Troy Balderson (R),  Michael Baumgartner (R),  Aaron Bean (R),  Cliff Bentz (R),  Robert Bresnahan (R),  Vern Buchanan (R),  Kat Cammack (R),  Mike Carey (R),  James Comer (R),  Dan Crenshaw (R),  Don Davis (D),  Neal Dunn (R),  Gabe Evans (R),  Julie Fedorchak (R),  Michelle Fischbach (R),  Scott Fitzgerald (R),  Brian Fitzpatrick (R),  Mike Flood (R),  Russell Fry (R),  Craig Goldman (R),  Mike Haridopolos (R),  Pat Harrigan (R),  Andy Harris (R),  Diana Harshbarger (R),  Kevin Hern (R),  French Hill (R),  Ashley Hinson (R),  Erin Houchin (R),  Richard Hudson (R),  Brian Jack (R),  Tom Kean (R),  Mike Kelly (R),  Brad Knott (R),  David Kustoff (R),  Bob Latta (R),  Nicole Malliotakis (R),  Richard McCormick (R),  Addison McDowell (R),  Carol Miller (R),  Mariannette Miller-Meeks (R),  Tim Moore (R),  Nathaniel Moran (R),  Zach Nunn (R),  Andy Ogles (R),  August Pfluger (R),  David Rouzer (R),  Michael Rulli (R),  Jefferson Shreve (R),  Lloyd Smucker (R),  Bryan Steil (R),  Greg Steube (R),  Claudia Tenney (R),  Beth Van Duyne (R),  Randy Weber (R),  Rudy Yakym (R), 

Last Action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (on 02/21/2025)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...